Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Rectal Cancer | Research article

Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis

Authors: Zhao-Wen Luo, Ming-Gu Zhu, Zhi-Qiao Zhang, Feng-Jun Ye, Wen-Heng Huang, Xue-Zhang Luo

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

The prognostic value of Ki-67 expression in colorectal cancer patients was controversial. Therefore, this meta analysis was conducted to ascertain the prognostic value of Ki-67 expression in colorectal cancer patients.

Methods

The electronic databases, including EMBASE, PubMed, Cochrane Library and Web of Knowledge database, were searched from January 1970 to July 2017. The pooled hazard ratios and 95% confidence intervals were calculated to evaluate the prognostic value of Ki-67 expression for colorectal cancer patients.

Results

Totally 34 eligible studies and 6180 colorectal cancer patients were included in the present meta analysis. The pooled hazard ratios were 1.54(95% CI 1.17–2.02, P = 0.005) for overall survival and 1.43(1.12–1.83, P = 0.008) for disease free survival in univariate analysis. After adjustment of other prognostic factors, the pooled HR was 1.50(95% CI 1.02–2.22, P = 0.03) for overall survival in multivariate analysis.

Conclusion

The present meta analysis demonstrated that high Ki-67 expression is significantly correlated with poor overall survival and disease free survival, indicating that high Ki-67 expression may serve as a valuable predictive method for poor prognosis of colorectal cancer patients.
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86.CrossRef
2.
Huh JW, Lee JH, Kim HR. Expression of p16, p53, and Ki-67 in colorectal adenocarcinoma: a study of 356 surgically resected cases. Hepato-Gastroenterology. 2010;57:734–40.PubMed
3.
Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, Murray FE. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 1999;282:1254–7.PubMedCrossRef
4.
Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993;123(3):513–22.CrossRef
5.
Meyer A, Merkel S, Bruckl W, Schellerer V, Schildberg C, Campean V, Hohenberger W, Croner RS. Cdc2 as prognostic marker in stage UICC II colon carcinomas. Eur J Cancer. 2009;45(8):1466–73.PubMedCrossRef
6.
Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O'Connell MJ, et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a north central Cancer treatment group study. J Clin Oncol. 2004;22(9):1572–82.PubMedCrossRef
7.
Fodor IK, Hutchins GG, Espiritu C, Quirke P, Jubb AM. Prognostic and predictive significance of proliferation in 867 colorectal cancers. J Clin Pathol. 2012;65(11):989–95.PubMedCrossRef
8.
Salminen E, Palmu S, Vahlberg T, Roberts PJ, Soderstrom KO. Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol. 2005;11(21):3245–9.PubMedPubMedCentralCrossRef
9.
Zhang Z, Wang M, Zhou L, Feng X, Cheng J, Yu Y, Gong Y, Zhu Y, Li C, Tian L, et al. Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. J Exp Clin Cancer Res. 2015;34:51.PubMedPubMedCentralCrossRef
10.
Yoshimura H, Dhar DK, Nakamoto T, Kotoh T, Takano M, Soma G, Nagasue N. Prognostic significance of tumor necrosis factor receptor in colorectal adenocarcinoma. Anticancer Res. 2003;23(1A):85–9.PubMed
11.
Li DW, Tang HM, Fan JW, Yan DW, Zhou CZ, Li SX, Wang XL, Peng ZH. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol. 2010;136(7):997–1006.PubMedCrossRef
12.
Li D, Peng X, Yan D, Tang H, Huang F, Yang Y, Peng Z. Msi-1 is a predictor of survival and a novel therapeutic target in colon cancer. Ann Surg Oncol. 2011;18(7):2074–83.PubMedCrossRef
13.
Dawson H, Koelzer VH, Karamitopoulou E, Economou M, Hammer C, Muller DE, Lugli A, Zlobec I. The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology. 2014;64(4):577–84.PubMedCrossRef
14.
Weber JC, Nakano H, Bachellier P, Oussoultzoglou E, Inoue K, Shimura H, Wolf P, Chenard-Neu MP, Jaeck D. Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg. 2001;182(1):81–8.PubMedCrossRef
15.
Xi HQ, Zhao P. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol. 2011;64(6):498–503.PubMedCrossRef
16.
Ivanecz A, Kavalar R, Palfy M, Pivec V, Sremec M, Horvat M, Potrc S. Can we improve the clinical risk score? The prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases. HPB (Oxford). 2014;16(3):235–42.CrossRef
17.
Rosati G, Chiacchio R, Reggiardo G, De Sanctis D, Manzione L. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival. Tumour Biol. 2004;25(5–6):258–63.PubMedCrossRef
18.
Nishihara K, Shomori K, Tamura T, Fujioka S, Ogawa T, Ito H. Immunohistochemical expression of geminin in colorectal cancer: implication of prognostic significance. Oncol Rep. 2009;21(5):1189–95.PubMed
19.
Scopa CD, Tsamandas AC, Zolota V, Kalofonos HP, Batistatou A, Vagianos C. Potential role of bcl-2 and ki-67 expression and apoptosis in colorectal carcinoma: a clinicopathologic study. Dig Dis Sci. 2003;48(10):1990–7.PubMedCrossRef
20.
Visca P, Alo PL, Del NF, Botti C, Trombetta G, Marandino F, Filippi S, Di Tondo U, Donnorso RP. Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa. Clin Cancer Res. 1999;5(12):4111–8.PubMed
21.
Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi T. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin a as an indicator of poor prognosis. Int J Cancer. 1999;84(3):225–33.CrossRef
22.
Bahnassy AA, Zekri AR, El-Houssini S, El-Shehaby AM, Mahmoud MR, Abdallah S, El-Serafi M. Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol. 2004;4:22.PubMedPubMedCentralCrossRef
23.
Buglioni S, D'Agnano I, Cosimelli M, Vasselli S, D'Angelo C, Tedesco M, Zupi G, Mottolese M. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int J Cancer. 1999;84(6):545–52.PubMedCrossRef
24.
Bertolini F, Bengala C, Losi L, Pagano M, Iachetta F, Dealis C, Jovic G, Depenni R, Zironi S, Falchi AM, et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;68(5):1455–61.PubMedCrossRef
25.
Kimura T, Tanaka S, Haruma K, Sumii K, Kajiyama G, Shimamoto F, Kohon N. Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol. 2000;16(1):55–64.PubMed
26.
Fernandez-Cebrian JM, Nevado SM, Vorwald KP, Pardo DLM, Martin-Cavanna J, Pacheco MP, Fernández Escudero B, Ramos FM. Can the clinical outcome in stage II colon carcinomas be predicted by determination of molecular marker expression? Clin Transl Oncol. 2007;9(10):663–70.PubMedCrossRef
27.
Wu XS, Xi HQ, Chen L. Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World J Surg Oncol. 2012;10:244.PubMedPubMedCentralCrossRef
28.
Furudoi A, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology. 2001;60(2):162–9.PubMedCrossRef
29.
Lin MX, Wen ZF, Feng ZY, He D. Expression and significance of Bmi-1 and Ki67 in colorectal carcinoma tissues. Ai Zheng. 2008;27(12):1321–6 [Article in Chinese].PubMed
30.
Hayashi H, Beppu T, Sakamoto Y, Miyamoto Y, Yokoyama N, Higashi T, Nitta H, Hashimoto D, Chikamoto A, Baba H. Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases. Am J Cancer Res. 2015;5(3):1225–33.PubMedPubMedCentral
31.
Ajani JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid A. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci. 2010;55(4):98–105.CrossRef
32.
Li D, Yan D, Tang H, Zhou C, Fan J, Li S, Wang X, Xia J, Huang F, Qiu G, et al. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 2009;16(12):3499–506.PubMedCrossRef
33.
Hu TH, Lin JW, Chen HH, Liu LF, Chuah SK, Tai MH. The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors. Dis Colon Rectum. 2009;52(2):319–26.PubMedCrossRef
34.
Roxburgh CS, Richards CH, Macdonald AI, Powell AG, McGlynn LM, McMillan DC, Horgan PG, Edwards J, Shiels PG. The in situ local immune response, tumour senescence and proliferation in colorectal cancer. Br J Cancer. 2013;109(8):2207–16.PubMedPubMedCentralCrossRef
35.
Shin IY, Sung NY, Lee YS, Kwon TS, Si Y, Lee YS, Oh ST, Lee IK. The expression of multiple proteins as prognostic factors in colorectal cancer: cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67. Gut Liver. 2014;8(1):13–23.PubMedCrossRef
36.
Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS, Kemeny N, Paty PB. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol. 2010;17(2):572–8.PubMedCrossRef
37.
Prall F, Ostwald C, Nizze H, Barten M. Expression profiling of colorectal carcinomas using tissue microarrays: cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis. Appl Immunohistochem Mol Morphol. 2004;12(2):111–21.PubMedCrossRef
38.
Zlobec I, Baker K, Terracciano L, Peter S, Degen L, Beglinger C, Lugli A. Two-marker protein profile predicts poor prognosis in patients with early rectal cancer. Br J Cancer. 2008;99(10):1712–7.PubMedPubMedCentralCrossRef
39.
Stroup DF, Berlin JA, Morton SC, Williamson GD, Rennie D, Moher D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta analysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.PubMedCrossRef
40.
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61:991–6.PubMedCrossRef
41.
Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M 3rd, Shipley WU, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy and androgen deprivation: Radiation Therapy Oncology Group Trial 92–02. J Clin Oncol. 2004;22:2133–40.PubMedCrossRef
42.
Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin RA, et al. Prognostic value of kroniek anhydrase IX and Ki67 as predictor of survival for renal clear cell cancer. J Urol. 2004;171:2461–6.PubMedCrossRef
43.
Tisell LE, Oden A, Muth A, Altiparmak G, Molne J, Ahlman H, Nilsson O. The Ki67 index a prognostic marker in medullary thyroid carcinoma. Br J Cancer. 2003;89:2093–7.PubMedPubMedCentralCrossRef
Metadata
Title
Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis
Authors
Zhao-Wen Luo
Ming-Gu Zhu
Zhi-Qiao Zhang
Feng-Jun Ye
Wen-Heng Huang
Xue-Zhang Luo
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5324-y

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

A new mouse model to study the role of ectopic Nanos3 expression in cancer

Research article

Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study

Research article

The prognostic impact of GSTM1/GSTP1 genetic variants in bladder Cancer

Research article

Development and validation of case-finding algorithms for recurrence of breast cancer using routinely collected administrative data

Research article

Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer

Research article

Human papillomavirus type 18 oncoproteins exert their oncogenicity in esophageal and tongue squamous cell carcinoma cell lines distinctly
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits